Tags: Drug.
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e. increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ.Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
